Tandem Diabetes Care, Inc. announced the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
